The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. The clinical heterogeneity of HCC, and the lack of good diagnostic markers and treatment strategies, has rendered the disease a major challenge. Patients with HCC have a highly variable clinical course, indicating that HCC comprises several biologically distinctive subgroups reflecting a molecular heterogeneity of the tumors. Transforming growth factor β (TGF-β) is known to exhibit tumor stage dependent suppressive (that is, growth inhibition) and oncogenic (that is, invasiveness) properties. Here, we asked if a TGF-β specific gene expression signature could refine the classification and prognostic predictions for HCC patients. Applying a comparative functional genomics approach we demonstrated that a temporal TGF-β gene expression signature established in mouse primary hepatocytes successfully discriminated distinct subgroups of HCC. The TGF-β positive cluster included two novel homogeneous groups of HCC associated with early and late TGF-β signatures. Kaplan-Meier plots and log-rank statistics indicated that the patients with a late TGF-β signature showed significantly ( P < 0.005) shortened mean survival time (16.2 ± 5.3 months) compared to the patients with an early (60.7 ± 16.1 months) TGF-β signature. Also, tumors expressing late TGF-β-responsive genes displayed invasive phenotype and increased tumor recurrence. We also showed that the late TGF-β signature accurately predicted liver metastasis and discriminated HCC cell lines by degree of invasiveness. Finally, we established that the TGF-β gene expression signature possessed a predictive value for tumors other than HCC. Conclusion: These data demonstrate the clinical significance of the genes embedded in TGF-β expression signature for the molecular classification of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
Massagué, J., Seoane, J., & Wotton, D. (2005) · Genes & Development · doi:10.1101/gad.1350705 · Cited by 2,452
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Massagué, J. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043051 · Cited by 1,899
Cited by
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Mechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
The cytoprotective role of the Keap1–Nrf2 pathway
Baird, L., & Dinkova-Kostova, A. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0674-5 · Cited by 1,027
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Chinese Human Proteome Project (CNHPP) Consortium, Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., et al. (2019) · Nature · doi:10.1038/s41586-019-0987-8 · Cited by 947
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., & Thorgeirsson, S. S. (2009) · Oncogene · doi:10.1038/onc.2009.211 · Cited by 733
Self-citationDai, Y., Somoza, R. A., Wang, L., Welter, J. F., Li, Y., Caplan, A. I., & Liu, C. C. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910772 · Cited by 660
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Role of epithelial to mesenchymal transition in hepatocellular carcinoma
Giannelli, G., Koudelkova, P., Dituri, F., & Mikulits, W. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.007 · Cited by 615
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
TGF‐β signalling and liver disease
Fabregat, I., Moreno‐Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., ten Dijke, P., & the IT‐LIVER Consortium (2016) · The FEBS Journal · doi:10.1111/febs.13665 · Cited by 600
Kumar, V., Ramnarayanan, K., Sundar, R., Padmanabhan, N., Srivastava, S., Koiwa, M., Yasuda, T., Koh, V., Huang, K. K., Tay, S. T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0683 · Cited by 573
Villanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornella, H., Liberzon, A., Kobayashi, M., Kumada, H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.006 · Cited by 447
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Yang, J. D., Nakamura, I., & Roberts, L. R. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.007 · Cited by 390
Rajski, M., Zanetti-Dällenbach, R., Vogel, B., Herrmann, R., Rochlitz, C., & Buess, M. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-1 · Cited by 355
Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
Fabregat, I., & Caballero-Díaz, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00357 · Cited by 351
TGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3
Wang, B., Hsu, S. H., Majumder, S., Kutay, H., Huang, W., Jacob, S. T., & Ghoshal, K. (2010) · Oncogene · doi:10.1038/onc.2009.468 · Cited by 348
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., Rodriguez–Carunchio, L., Solé, M., Thung, S., Stanger, B. Z., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.002 · Cited by 318
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Dysregulation of apoptosis in hepatocellular carcinoma cells
Fabregat, I. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.513 · Cited by 280
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Elez, E., Tabernero, J., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 265
Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma
Giannelli, G., Villa, E., & Lahn, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0243 · Cited by 263
Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
Chen, J., Gingold, J. A., & Su, X. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.007 · Cited by 260
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
Bassaganyas, L., Pinyol, R., Esteban-Fabró, R., Torrens, L., Torrecilla, S., Willoughby, C. E., Franch-Expósito, S., Vila-Casadesús, M., Salaverria, I., Montal, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1497 · Cited by 58
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
Guégan, J.-P., Frémin, C., & Baffet, G. (2012) · International Journal of Hepatology · doi:10.1155/2012/328372 · Cited by 56
Metadata
- Authors
- Coulouarn, C., Factor, V. M., & Thorgeirsson, S. S.
- Venue
- Hepatology
- Published
- 2008-06
- Volume
- 47
- Issue
- 6
- Pages
- 2059-2067
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2085114559
- Cited by
- 332
- References
- 35
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.